The Chinese vaccine against the coronavirus fights all strains and can be applied massively in 2021 | The NY Journal

The Chinese pharmaceutical company Sinovac announced that its coronavirus vaccine fights all existing strains in the world and will be ready for mass application in 2021, since the company can produce 300 million doses annually thanks to the fact that it has a factory specifically dedicated to the drug.

While AstraZeneca’s vaccine and the University of Oxford partially halted their trials after finding that it produced inflammation of the spinal cord in a volunteer, Sinovac ensures that her CoronaVac It has not produced “special adverse reactions” in people who have received it in its Phase 3 trials.

During a media visit to the Sinovac facility in Beijing, the president of the pharmaceutical company, Yin Weidong, assured that his CoronaVac can “combat all the strains of the coronavirus SARS-Cov-2 existing in the world” and that about 90 percent of the company’s employees in the world and their families have already received their doses.

What you should know about this experimental vaccine

Sinovac tried seven different methods for its vaccine, but, according to Yin, found that “The inactivated vaccine route was the best”.

CoronaVac is now being tested in Brazil, Turkey, Bangladesh and Indonesia, because “it is better to do the tests abroad because in China the pandemic is practically controlled”, according to the president of Sinovac.

On September 9, Sinovac announced that the results of the CoronaVac vaccine trials in phases 1 and 2 had shown “good safety and immunogenicity” in healthy adults over the age of 60, and in people aged 18 to 59.

Antibody levels in those over 60 were slightly lower than those found in the tests with a younger population, according to the company. Ensuring that the vaccine can be applied to the entire population, including children and adolescents, is one of the keys to preventing outbreaks of the virus in schools and daycare centers.

Sinovac’s vaccine, which in Latin America it is produced in cooperation with the Brazilian institute Butantan, based in Sao Paulo, is in the last phase of large-scale adult trials in countries such as Brazil, Indonesia or Turkey.

CoronaVac has secured 46 million doses in the South American country until December and another 16 million for the first quarter of 2012, according to the Brazilian authorities.

Four Chinese vaccines are currently in phase 3 of clinical trials – among a total of nine in the world – although one of the remaining five is part of a consortium formed by the Chinese Fosun Pharma, the German Biontech and the American Pfizer. The four totally Chinese are those of Sinovac, Sinopharm, the Wuhan Institute of Biological Products and that of Cansino Biologics, which began to be used in late June in the Chinese Army..

(With information from EFE)

---